Literature DB >> 2119471

Cytoprotective effect of TRK-100, a prostacyclin analogue, against chemical injuries in cultured human vascular endothelial cells.

A Sakai1, M Yajima, S Nishio.   

Abstract

We studied the cytoprotective effect of TRK-100, a chemically stable analogue of prostacyclin (PGI2), in the cultured human endothelial cells from umbilical vein. TRK-100 (10 and 100 nM) stimulated significantly proliferation of endothelial cells but did not affect PGI2 production in endothelial cells. Exposure of cultured endothelial cells to homocysteine (2.5 mM) or glucose (50 mM) caused concentration-dependent cytotoxicity, as evidenced by a decrease in number of viable cells. When endothelial cells were treated with TRK-100 simultaneously or prior to, but not after, exposure to injury substances, decreases in viable cell were significantly suppressed. The protective effect of TRK-100 against homocysteine-induced cytotoxicity also appeared in endothelial cells treated with acetylsalicylic acid, suggesting that endogenous PGI2 did not involve in the protective effect of TRK-100.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2119471     DOI: 10.1016/0024-3205(90)90626-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor.

Authors:  Sarah J O'Meara; B Therese Kinsella
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

2.  The effects of the statins lovastatin and cerivastatin on signalling by the prostanoid IP-receptor.

Authors:  O A Lawler; S M Miggin; B T Kinsella
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

3.  Interaction of the human prostacyclin receptor with Rab11: characterization of a novel Rab11 binding domain within alpha-helix 8 that is regulated by palmitoylation.

Authors:  Helen M Reid; Eamon P Mulvaney; Elizebeth C Turner; B Therese Kinsella
Journal:  J Biol Chem       Date:  2010-04-15       Impact factor: 5.157

4.  Regulation of the human prostacyclin receptor gene by the cholesterol-responsive SREBP1.

Authors:  Elizebeth C Turner; B Therese Kinsella
Journal:  J Lipid Res       Date:  2012-09-11       Impact factor: 5.922

5.  Suppression of pseudointimal hyperplasia by a novel prostacyclin analogue: beraprost.

Authors:  D I Kim; J Kambayashi; T Shibuya; M Sakon; T Kawasaki; T Mori
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

6.  A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design.

Authors:  Hidetomo Nakamoto; Toshiro Fujita; Hideki Origasa; Masanao Isono; Hajimu Kurumatani; Kiyonobu Okada; Hiroyuki Kanoh; Takashi Kiriyama; Shunsuke Yamada
Journal:  BMC Nephrol       Date:  2014-09-19       Impact factor: 2.388

7.  Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial.

Authors:  Akio Koyama; Toshiro Fujita; Fumitake Gejyo; Hideki Origasa; Masanao Isono; Hajimu Kurumatani; Kiyonobu Okada; Hiroyuki Kanoh; Takashi Kiriyama; Shunsuke Yamada
Journal:  BMC Nephrol       Date:  2015-10-16       Impact factor: 2.388

8.  Agonist-dependent internalization and trafficking of the human prostacyclin receptor: a direct role for Rab5a GTPase.

Authors:  Martina B O'Keeffe; Helen M Reid; B Therese Kinsella
Journal:  Biochim Biophys Acta       Date:  2008-05-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.